<DOC>
	<DOCNO>NCT01210404</DOCNO>
	<brief_summary>Filibuvir , CYP3A4 inhibitor develop treatment chronic Hepatitis C infection . Given likelihood co administration filibuvir methadone , study evaluate effect filibuvir pharmacokinetics R/S Methadone .</brief_summary>
	<brief_title>Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Males female , without evidence infection HIV , HBV HCV , chronic methadone maintenance least three month stable dose least 1 week prior study start . Evidence chronic disease include HIV , HBV HCV . Evidence acute chronic liver disease . Treatment prescription nonprescription drug methadone within 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Drug interaction methadone .</keyword>
</DOC>